DAGYNIL 1.25mg Price

Overview

Welcome to Dwaey, specifically on DAGYNIL 1.25mg Tablets page.
This medicine contains an important and useful components, as it consists of Oestrogens (conjugated).
DAGYNIL 1.25mg is available in the market in concentration 1.25mg/Tablet and in the form of Tablets.

DAGRA PHARMACEUTICALS is the producer of DAGYNIL 1.25mg and it is imported from NETHERLANDS, The most popular alternatives of DAGYNIL 1.25mg are listed downward .

Mode Of Action

Activity against HSV types I and II and varicella-zoster virus is due to intracellular conversion of aciclovir to the monophosphate by viral thymidine kinase with subsequent conversion to the diphosphate and active triphosphate by cellular enzymes. This active form inhibits viral DNA synthesis and replication by interfering with viral DNA polymerase enzyme and being incorporated into viral DNA.

Indication

• Herpes simplex infections
• Varicella zoster (chickenpox)
• Herpes zoster (shingles)
• Genital herpes

Precaution

Renal impairment. Pregnancy, lactation. Neurological abnormalities with significant hypoxia, serious hepatic or electrolyte abnormalities. Maintain adequate hydration. Lactation: Drug enters breast milk; use with caution.

Side Effects

• >10% Oral Malaise (<12%) 1-10% Parenteral Inflammation or phlebitis at injection site (9%)
• Nausea (7%)
• Vomiting (7%)
• Rash or hives (2%)
• Elevated transaminase levels (1-2%) Oral Nausea (2-5%)
• Vomiting (<3%)
• Diarrhea (2-3%)
• Headache (2%) <1% Abdominal pain
• Aggression/confusion
• Agitation
• Alopecia
• Anaphylaxis
• Anemia
• Angioedema
• Anorexia
• Ataxia
• Coma
• Disseminated intravascular coagulation (DIC)
• Dizziness
• Fatigue Potentially Fatal: Occasionally neurotoxicity after IV use: Lethargy
• confusion
• agitation
• tremors
• seizures
• coma.

Contra indication

Hypersensitivity.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.